ArticleJournal of neuro-oncology2013
Anaplastic PXA in adults: case series with clinicopathologic and molecular features.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Thalamic pleomorphic xanthoastrocytoma central nervous system World Health Organization grade 3.Radiology case reports · 2025Article
- Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients.Scientific reports · 2024Article
- Diffusely Infiltrating Gliomas With Poor Prognosis,Neurosurgery practice · 2023Article
- Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.Current oncology (Toronto, Ont.) · 2023Article
- Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas.Journal of neuro-oncology · 2021Article
- Low-grade developmental and epilepsy associated brain tumors: a critical update 2020.Acta neuropathologica communications · 2020Review
- Anaplastic Pleomorphic Xanthoastrocytoma: A Case Report and Literature Review.International journal of general medicine · 2020Article
- Rare clinical presentations of pleomorphic xanthoastrocytoma with a high proliferative index: Two case reports.Medicine · 2020Article
- Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.Journal of neuro-oncology · 2019Article
- Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.Brain tumor pathology · 2019Review
- Papillary glioblastoma exhibiting a neuroradiological cyst with a mural nodule: A case report.Medicine · 2019Article
- Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.Journal of neuro-oncology · 2018Article
- Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes.Scientific reports · 2018Article
- Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.Brain pathology (Zurich, Switzerland) · 2018Article
- Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.Journal of neuro-oncology · 2018Article
- Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.Journal of cancer research and clinical oncology · 2016Article
- Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.Brain pathology (Zurich, Switzerland) · 2015Article
- BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.The American journal of surgical pathology · 2015Article
- Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases.American journal of clinical pathology · 2014Article
- BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.Brain pathology (Zurich, Switzerland) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pleomorphic xanthoastrocytomas with anaplastic features (PXA-As) are rare tumors about which little is known regarding clinicopathologic and molecular features. Several studies have identified BRAF V600E mutations in PXA-As, but the percentage with mutation may differ between adult and pediatric examples, and limited information exists about immunohistochemistry for isocitrate dehydrogenase 1 (IDH1). Ten cases of adult PXA-As seen at our institution since 2000 were assessed for BRAF V600E mutation by polymerase chain reaction testing (PCR) and IDH1 by immunohistochemistry. Patients ranged in age from 18-68 years; four PXA-As affected temporal lobe and two were cystic. Four patients underwent gross total resection and 9 of 10 patients received cranial irradiation and/or adjuvant chemotherapy. Five survived less than 5 years, although 2 of 5 patients died from non-tumor causes. Four long-term survivors are alive at 7.5, 9.8, 11.4, and 11.9 years post-diagnosis. Two of four long term survivors had BRAF V600E mutation: patients were ages 18 and 28 years. A 48-year-old male without BRAF mutation survives at 9.8 years, even with thalamic location; conversely a 68-year-old female with temporal lobe tumor and BRAF mutation survived 1.9 years after diagnosis. All tumors were IDH1 immunonegative. This case series details clinicopathologic features of a subset of rare PXA-As in adults. BRAF V600E mutation was identified in 50 % of these cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.